 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| lesabelimab (BC003) / Guilin SanJin Group, CDP-1 (cetuximab biosimilar) / Guilin SanJin Group
New P1 trial, Metastases: An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - Feb 4, 2021
P1, N=130, Recruiting, Sponsor: Dragonboat Biopharmaceutical Company Limited
- |||| BC003 / Guilin SanJin Group
New P2 trial: the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors (clinicaltrials.gov) - Jan 21, 2021
P2, N=127, Recruiting, Sponsor: Dragonboat Biopharmaceutical Company Limited
- ||| BC003 / Guilin SanJin Group
Enrollment open, Metastases: Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Nov 7, 2019
P1, N=130, Recruiting, Sponsor: Dragonboat Biopharmaceutical Company Limited
Not yet recruiting --> Recruiting
- ||| BC003 / Guilin SanJin Group
New P1 trial, Metastases: Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Apr 8, 2019
P1, N=130, Not yet recruiting, Sponsor: Dragonboat Biopharmaceutical Company Limited